You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Policy & Regulation
Veralox Therapeutics Submits IND to US FDA for Phase I Trial of VLX-1005 to Treat Heparin-Inducted Thrombocytopenia
Login
Username:

Password:


Related Headlines

Akeso's ivonescimab meets overall survival endpoint in interim analysis of Phase III HARMONi-2 study

Teva reports positive Phase 2a data for TEV '408 in celiac disease

Ono Pharma partners with Aitia on neurological disease drug discovery

BioMarin completes Alesta Therapeutics acquisition

BioViva receives US patent for Klotho gene therapy targeting age-related cognitive decline

AstraZeneca completes global licence agreement for Zegfrovy

AstraZeneca and Daiichi Sankyo's Enhertu plus pertuzumab approved in EU for first-line HER2-positive metastatic breast cancer

NeuroSense reveals strategy to advance PrimeC toward potential ALS approval

UCB agrees with US government to lower medicine costs and strengthen US manufacturing

BioArctic and Eisai announce final positive recommendation from Canada's Drug Agency supporting public reimbursement of Leqembi

Karyopharm seeks accelerated FDA approval for selinexor–ruxolitinib in myelofibrosis

Lilly to acquire Merida Biosciences in USD2.875bn deal

Harvest Integrated Research Organization signs MoU with Differentia Biotech

Ascletis Pharma Inc doses first participant in global Phase III clinical programme of ASC30

Zambon receives European Commission approval for Hopledo in Parkinson's disease

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026